CClinicalTrials.gg
Status unknownNCT02956304SIMULANG-TMSUpdated Apr 28, 2017

" Effect of Affordance of Objects on the Memory: Study in Transcranial Magnetic Stimulation "

An interventional study of PMv stimulation (iTBS) and PMv inhibition (cTBS) in Healthy, sponsored by Centre Hospitalier St Anne. Status unknown at 1 site in France. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-28.

Sponsored by Centre Hospitalier St Anne · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Apr 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

The purpose of this study is determine the involvement of motor system in the memory of manipulable objects. The idea is to stimulate the ventral premotor cortex with transcranial magnetic stimulation to see whether this stimulation will affect memory of manipulable objects.

Read the detailed description

Embodied cognition claims that representations shares processing resources with sensorimotor systems. More specifically, it has been proposed that language comprehension relies on internal simulation of the meaning. For instance, numerous studies have shown that the processing of action-related concepts involve a motor activation similar to when the action is actually performed. However, even if those studies show clearly that action-related concepts involve a motor activation, such activations may be incidental to the activation of their representations, rather than part of it. Another way to show that this motor component takes part in the representation of manipulable objetcs is to investigate whether an impairment of motor system would impair the memory of manipulable object. In this study, investigators will use Transcranial Magnetic Stimulation (TMS) to stimulate ventral premotor cortex (PMv) to see whether this stimulation will affect memory of manipulable objects, but not memory of nonmanipulable objects. For this purpose, three TMS conditions will be assessed: cTBS to inhibit the motor cortex, iTBS to excite the motor cortex, and a SHAM condition as control.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Centre Hospitalier St Anne is the lead sponsor of 99 studies on the registry; 53 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 18 and 35 years
  • Right-handers (score between 70 and 100 on the scale of Edinburgh)
  • Native language : French
  • Not depressed (score lower than 14 in the BDI)
  • health insurance
  • Consent

Exclusion criteria

Exclusion Criteria:

  • Psychiatric family history up to the second degree
  • Medical treatment, in particular psychotropic being able to affect the memory and the attention
  • view or hearing disorders (not compensated)
  • neurological histories (epilepsy, alcoholism in particular) or psychiatric or important memory complaints
  • Contraindications for the SMT
  • contraindications in the MRI
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Group iTBS-cTBS-SHAM

    PMv stimulation (iTBS) at session 2, PMv inhibition (cTBS) at session 3, and control (SHAM) at session 4

    Other: PMv stimulation (iTBS) · Other: PMv inhibition (cTBS) · Other: Control (SHAM)

  • Other
    Group iTBS-SHAM-cTBS

    PMv stimulation (iTBS) at session 2, control (SHAM) at session 3, and PMv inhibition (cTBS) at session 4

    Other: PMv stimulation (iTBS) · Other: PMv inhibition (cTBS) · Other: Control (SHAM)

  • Other
    Group cTBS-iTBS-SHAM

    PMv inhibition (cTBS) at session 2, PMv stimulation (iTBS) at session 3, and control (SHAM) at session 4

    Other: PMv stimulation (iTBS) · Other: PMv inhibition (cTBS) · Other: Control (SHAM)

  • Other
    Group cTBS-SHAM-iTBS

    PMv inhibition (cTBS) at session 2, control (SHAM) at session 3, and PMv stimulation (iTBS) at session 4

    Other: PMv stimulation (iTBS) · Other: PMv inhibition (cTBS) · Other: Control (SHAM)

  • Other
    Group SHAM-iTBS-cTBS

    control (SHAM) at session 2, PMv stimulation (iTBS) at session 3, and PMv inhibition (cTBS) at session 4

    Other: PMv stimulation (iTBS) · Other: PMv inhibition (cTBS) · Other: Control (SHAM)

  • Other
    Group SHAM-cTBS-iTBS

    control (SHAM) at session 2, PMv inhibition (cTBS) at session 3, and PMv stimulation (iTBS) at session 4

    Other: PMv stimulation (iTBS) · Other: PMv inhibition (cTBS) · Other: Control (SHAM)

Interventions

  • OtherPMv stimulation (iTBS)

    PMv stimulation (iTBS)

  • OtherPMv inhibition (cTBS)

    PMv inhibition (cTBS)

  • OtherControl (SHAM)

    Control (SHAM)

06

What researchers measure

Primary outcomes

  1. Number of objects affordants and of objects not - affordants reminded

    Measure of the number of objects affordants and of objects not - affordants reminded according to if the stimulation is in PMv or control

    Time frame: 1 week

  2. Number of objects affordants and of objects not - affordants reminded

    Measure of the number of objects affordants and of objects not - affordants reminded according to if the stimulation is in PMv or control

    Time frame: 2 weeks

  3. Number of objects affordants and of objects not - affordants reminded

    Measure of the number of objects affordants and of objects not - affordants reminded according to if the stimulation is in PMv or control

    Time frame: 3 weeks

Secondary outcomes

  1. Number of object reminded

    Measure of the number of objects affordants and of objects not - affordants reminded according to if the stimulation is excitation or control

    Time frame: 1 week

  2. Number of object reminded

    Measure of the number of objects affordants and of objects not - affordants reminded according to if the stimulation is excitation or control

    Time frame: 2 weeks

  3. Number of object reminded

    Measure of the number of objects affordants and of objects not - affordants reminded according to if the stimulation is excitation or control

    Time frame: 3 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02956304
Lead sponsor
Centre Hospitalier St Anne
Collaborators
University of Paris 5 - Rene Descartes
Responsible party
Sponsor
First posted
Nov 6, 2016
Start date
Apr 3, 2017
Primary completion
Jul 2018 (estimated)
Completion
Nov 2018 (estimated)
Last update
Apr 28, 2017

Study contacts

Benoit CREPON, MD
Contact
b.crepon@ch-sainte-anne.fr
00 33 1 45 65 87 70
Marie GODARD
Contact
marie.godard@aphp.fr
00 33 1 45 65 77 28
Pascale PIOLINO
study director · University of Paris 5 - Rene Descartes
Benoit CREPON, MD
study director · CHSA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion